首页> 外文期刊>Vaccine >A genetically engineered prime-boost vaccination strategy for oculonasal delivery with poly(d,l-lactic-co-glycolic acid) microparticles against infection of turkeys with avian Metapneumovirus.
【24h】

A genetically engineered prime-boost vaccination strategy for oculonasal delivery with poly(d,l-lactic-co-glycolic acid) microparticles against infection of turkeys with avian Metapneumovirus.

机译:一种经基因工程的初免-加强接种策略,用于用聚(d,l-乳酸-乙醇酸共聚物)微粒进行眼鼻送递,以防止禽类间质肺病毒感染火鸡。

获取原文
获取原文并翻译 | 示例
           

摘要

In this study we demonstrated the use of an oculonasally delivered poly(d,l-lactic-co-glycolic acid) microparticle (PLGA-MP)-based and genetically engineered vaccination strategy in the avian system. An avian Metapneumovirus (aMPV) fusion (F) protein-encoding plasmid vaccine and the corresponding recombinant protein vaccine were produced and bound to or encapsulated by PLGA-MP, respectively. The PLGA-MP as the controlled release system was shown in vitro to not induce any cytopathic effects and to efficiently deliver the F protein-based aMPV-vaccines to avian cells for further processing. Vaccination of turkeys was carried out by priming with an MP-bound F protein-encoding plasmid vaccine and a booster-vaccination with an MP-encapsulated recombinant F protein. Besides the prime-boost F-specific vaccinated birds, negative control birds inoculated with a mock-MP prime-boost regimen as well as non-vaccinated birds and live vaccinated positive control birds were included in the study. The MP-based immunization of turkeys via the oculonasal route induced systemic humoral immune reactions as well as local and systemic cellular immune reactions, and had no adverse effects on the upper respiratory tract. The F protein-specific prime-boost strategy induced partial protection. After challenge the F protein-specific MP-vaccinated birds showed less clinical signs and histopathological lesions than control birds of mock MP-vaccinated and non-vaccinated groups did. The vaccination improved viral clearance and induced accumulation of local and systemic CD4+ T cells when compared to the mock MP-vaccination. It also induced systemic aMPV-neutralizing antibodies. The comparison of mock- and F protein-specific MP-vaccinated birds to non-vaccinated control birds suggests that aMPV-specific effects as well as adjuvant effects mediated by MP may have contributed to the overall protective effect.
机译:在这项研究中,我们证明了在鸟类系统中使用经眼鼻递送的聚(d,l-乳酸-乙醇酸)微粒(PLGA-MP)基于基因工程的疫苗接种策略。产生了禽偏肺病毒(aMPV)融合蛋白(F)的质粒疫苗和相应的重组蛋白疫苗,并分别与PLGA-MP结合或封装。 PLGA-MP作为控释系统在体外显示出不会诱导任何细胞病变作用,并且可以将基于F蛋白的aMPV疫苗有效地递送至禽类细胞进行进一步处理。火鸡的疫苗接种方法是:先将MP结合的F蛋白编码质粒疫苗接种,再用MP包封的重组F蛋白加强疫苗接种。除了初免-F特异接种疫苗的鸟类外,还接种了模拟MP-初免-强化方案的阴性对照鸟类,未接种的鸟类和活疫苗阳性对照鸟类。火鸡通过眼鼻途径的MP免疫引起全身性体液免疫反应以及局部和全身性细胞免疫反应,并且对上呼吸道无不利影响。 F蛋白特异性的初免-加强策略诱导了部分保护。挑战后,F蛋白特异性MP疫苗接种的禽类比模拟MP疫苗接种和未接种疫苗的对照组显示出更少的临床体征和组织病理学损伤。与模拟MP疫苗相比,接种疫苗可提高病毒清除率,并诱导局部和全身CD4 + T细胞积累。它还诱导全身性aMPV中和抗体。接种MP-和F蛋白的MP-禽类与未经接种的对照禽类的比较表明,MPV-特异性作用以及MP介导的佐剂作用可能有助于总体保护作用。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号